期刊
LEUKEMIA & LYMPHOMA
卷 58, 期 6, 页码 1481-1487出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2016.1246733
关键词
Symptom burden; polycythemia vera; quality of life; phlebotomy
资金
- NCI NIH HHS [P30 CA054174] Funding Source: Medline
Current guidelines suggest that polycythemia vera (PV) patients maintain a strict hematocrit less than 45%. However, to date, little is known about the relationship between HCT control and PV- related symptom burden. In this study, PV patient data was analyzed from the CYTO PV trial (n=224) and the MPN-SAF study cohort (n=645). No significant differences in symptom burden were seen at the 6 and 12 month follow-up when evaluating prospective hematocrit control in the CYTO PV cohort. Patients in the MPN-SAF cohort with a worst item score of greater than 5/10 on the Myeloproliferative Neoplasm Symptom Total Symptom Score had a significantly lower mean hematocrit (p=.0376). These findings suggest a relationship between traditional aggressive therapy for PV and increased symptom burden with prolonged therapy. Thus, symptom burden should be considered when contemplating the choice of therapy in the second-line setting for PV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据